Jon Najarian Highlights Unusual Options Activity In Biogen

Biogen Inc BIIB traded sharply higher on Tuesday on better than expected earnings and positive news about its Alzheimer's drug. The company surprised investors by revealing that it will seek the regulatory approval of its Alzheimer's treatment.

Jon Najarian noticed some unusual options activity in the name after the sharp move higher. He said on CNBC's "Fast Money Halftime Report" that options traders were selling the October $300 calls in Biogen. Around 5,000 contracts were sold in the first half of the session on Tuesday as traders were betting that the stock won't continue to move higher, above $300.

Related Links:

Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis

Stamps.com Option Traders Hit The Jackpot On UPS News

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date of Trade
ticker
Put/Call
Strike Price
DTE
Sentiment
Posted In: OptionsMarketsMediaCNBCFast Money Halftime ReportJon Najarian
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!